CRISPR Therapeutics is still losing money, but it also finished March with $1.9 billion in cash after burning through $134 ...

Discover upcoming breakthroughs in Type 1 Diabetes & B-cell disorder treatments, market growth to $24B by 2031, and key ...

For 21-year-old Javarian Weatherspoon, life without pain feels like a miracle. After growing up with sickle cell disease, he ...

Sana Biotechnology, Inc.’s SANA share price has dipped by 5.61%, which has investors questioning if this is right time to buy ...

What if we could reprogramme the TME itself? Cutting-edge research suggests that engineered mesenchymal stem cells (MSCs) ...

Despite hitting a clinical “milestone,” Prime Medicine is shelving its sole clinical-stage genetic medicine. | Despite ...

Molnar, also renowned for his hazelnut breeding program, displayed the dogwood varieties to visitors at the Rutgers ...

Update before that proof-of-concept comes to bite Security researchers are sounding the alarm over a fresh flaw in the ...

UK-based startup Green Bioactives is preparing for the commercial launch of high-value botanicals made via plant cell culture ...

a HIP-modified, stem cell-derived pancreatic islet cell therapy. In addition to the human data for UP421 outlined above, Sana shared data for SC451 showing 15-month durability of glycemic control ...

Robot painting reveals technology’s limits, but true artistry lies in human-machine collaboration, not AI hype.